Paolo Strati, MD
Internal Medicine · Houston, TXNPI 1154737765
Payments from drug & device makers
Across 400 payments — averaging $48,122 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$12M
- Bristol Myers Squibb$2.6M
- Astrazeneca UK Limited$1.1M
- Acerta Pharma LLC$779K
- Gilead$757K
- Swedish Orphan Biovitrum AB$552K
- plus $1.4M from 17 others
Across 5 payments — averaging $162.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$814
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $12,030,679 |
| Bristol Myers Squibb | 10 | $2,585,242 |
| Astrazeneca UK Limited | 4 | $1,095,459 |
| Acerta Pharma LLC | 6 | $779,257 |
| Gilead(2 entities) | 90 | $757,301 |
| Swedish Orphan Biovitrum AB | 10 | $552,089 |
| ADC Therapeutics America, Inc. | 32 | $534,629 |
| AbbVie | 49 | $471,241 |
| Incyte Corporation | 33 | $328,011 |
| Pharmacyclics LLC, An Abbvie Company | 67 | $40,356 |
| Genmab U.S., Inc. | 19 | $20,986 |
| F. Hoffmann-la Roche AG | 13 | $14,706 |
| Genentech USA, Inc. | 14 | $14,516 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $7,875 |
| Beigene USA, Inc. | 6 | $4,920 |
| Novartis | 3 | $2,998 |
| Ipsen Biopharmaceuticals, Inc | 1 | $2,610 |
| TG Therapeutics, Inc. | 1 | $2,025 |
| Eli Lilly | 1 | $1,350 |
| Sobi, Inc | 9 | $1,244 |
| BTG International Inc. | 2 | $1,068 |
| Johnson & Johnson | 1 | $97 |
| Seagen Inc. | 1 | $21 |
How this compares
$19,248,680 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Houston
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Aung NaingHouston$30.6M
- Preetesh JainHouston$19.5M
- Nicholas ShortHouston$17.6M
- Isabella GlitzaHouston$14.8M
- Murtaza MussajiHouston$13.1M
- Hussein TawbiHouston$12.6M
- Hans LeeHouston$11.7M
- Dominick DaunnoHouston$11.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.